Find a lawyerOur capabilitiesYour careerSearch
Locations
Our capabilities
News

Select language:

Locations
Our capabilities
News

Select language:

hamburger menu showcase image
  1. Our capabilities
  2. Life sciences
Life sciences
hero-image-0
Guiding life sciences clients with global insight and cross-practice expertise

Developments in pharmaceuticals, biotech and MedTech are reshaping healthcare, offering new possibilities alongside complex legal and regulatory demands. Our work spans M&A and IP licensing, antitrust, litigation and international arbitration, data protection, product liability, and regulatory matters – supporting clients as they navigate this rapidly changing environment.

To deliver this, Freshfields provides a fully connected global team, helping clients with their most critical matters. We are deep-rooted in the industry with experience that informs everything we do. Many of our lawyers have scientific backgrounds and bring first-hand life sciences industry experience.

We have supported companies at various stages of growth, from early stage biotechs to large multinationals and investors.

Amid rapid global change, we are positioned to advise clients with new and ever-changing challenges.  AI is driving rapid change in the way the life sciences industry approaches research, development and regulatory challenges.  It is creating significant opportunities, alongside data and oversight concerns. Environmental considerations are prompting new reporting obligations. Competition authorities are becoming more rigorous in assessing life sciences and healthcare transactions. By tracking and anticipating these shifts globally, we help clients adapt to—and anticipate—change.

Related capabilities
Antitrust and competition
Artificial intelligence
Capital markets
Commercial litigation
Corporate advisory and governance
Data, privacy and cyber security
Employment, incentives and pensions
Foreign direct investment and national security
Intellectual property
International arbitration
International trade
Mergers and acquisitions
Private capital
Regulatory and compliance advisory
Restructuring
Sanctions
Securities and shareholder litigation
Tax
White-collar defense and corporate crime

Contacts

Contacts

Meet the team
New York
Adam GoldenGlobal Head of Life Sciences
Meet the team
Awards & recognition
Law360 2024
Life Sciences Practice Group of the Year
Chambers Global 2025
Ranked in Life Sciences
JUVE 2022-2024
Ranked #1 in Pharmaceutical and Healthcare Transactions
Chambers UK 2024
Ranked Band 1 in Life Sciences: Product Liability
Our thinking

Our thinking

Blog
Feb 14 2025
SPC protection for second medical uses post-Brexit - UK Court of Appeal clarifies test
The Court of Appeal has clarified that Brexit has not changed the test to determine whether supplementary protection certificate (SPC)...
Blog
Jan 28 2025
10 Key MedTech Themes for 2025
Note: this article originally ran in MedCity News The MedTech industry is accelerating at an unprecedented pace. As AI reshapes the...
Blog
Jan 27 2025
Life sciences – what to watch in 2025
We asked more than 200 Freshfields lawyers – across geographies and practice areas: what are the 1-2 issues top of mind for you and your...
Blog
Jan 24 2025
Final agreement on the European Health Data Space: Cross-border access to EU health data
After long debates between the Commission, Parliament and the Council, the Council has adopted the regulation of the European Health Data...
Blog
Jan 21 2025
The first significant overhaul of the UK clinical trials regime in two decades begins to take shape
In brief: On 12 December 2024, draft legislation to amend the Medicines for Human Use (Clinical Trials) Regulations 2004 was laid before...
Blog
Jan 15 2025
FTC Issues Second Interim Report on PBMs focused on Pricing Practices for Specialty Generic Drugs
On January 14, 2025, the Federal Trade Commission (FTC) unanimously agreed to publish its second interim staff report on pharmacy benefit...
Blog
Jan 13 2025
New Form, New Fees, and New Thresholds: FTC Announces HSR Act & Interlocking Directorate Thresholds and HSR Filing Fees for 2025
On January 10, 2025, the US Federal Trade Commission (FTC) announced its annual updates to the Hart-Scott-Rodino (HSR) Act reportability...
Blog
Dec 20 2024
UK medical devices regulatory reform: where are we now and what’s next for 2025?
In summary: The UK MHRA’s plans for reforming the medical devices regulatory framework post-Brexit have begun to take more concrete...
Blog
Dec 13 2024
New General Product Safety Regulation (GPSR) set to transform the EU product compliance framework
Today, on 13 December 2024, the new General Product Safety Regulation (GPSR) comes into force, introducing modernised safety standards...
Blog
Oct 10 2024
The EU Product Liability Directive: Key Implications for Software and AI
The European Union‘s updated Product Liability Directive (PLD), adopted by the European Council today and expected to come into effect in...
Blog
Sep 25 2024
New era for European compulsory licensing on the horizon?
On 26 June 2024, just days before the end of the Belgian presidency, the Council of the EU adopted its position on a proposed regulation...
Related capabilities
Antitrust and competitionArtificial intelligenceCapital marketsCommercial litigationCorporate advisory and governanceData, privacy and cyber securityEmployment, incentives and pensionsForeign direct investment and national securityIntellectual propertyInternational arbitrationInternational tradeMergers and acquisitionsPrivate capitalRegulatory and compliance advisoryRestructuringSanctionsSecurities and shareholder litigationTaxWhite-collar defense and corporate crime
Related capabilities
FIND US IN
All locations
NAVIGATE TO
About usYour careerOur thinkingOur capabilitiesNews
CONNECT
Find a lawyerAlumniContact us
NEED HELP
Fraud and scamsComplaintsTerms and conditions
LEGAL
AccessibilityCookiesLegal noticesTransparency in supply chains statementResponsible procurementPrivacy

© 2025 Freshfields. Attorney Advertising: prior results do not guarantee a similar outcome

Select language: